MCM
ANIP icon

McKinley Capital Management’s ANI Pharmaceuticals ANIP Stock Holding History

McKinley Capital Management’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-52,215
Closed -$3.46M – 484
2016
Q3 		$3.46M Buy
52,215
+9
+0% +$563 0.12% 152
2016
Q2 		$2.91M Sell
52,206
-86
-0.2% -$4.18K 0.14% 160
2016
Q1 		$1.76M Buy
+52,292
New +$1.77M 0.08% 192

Other funds holding ANIP

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

McKinley Capital Management's ANIP Position: Q4 2016 in Review

McKinley Capital Management sold out of ANI Pharmaceuticals (ANIP) in Q4 2016, closing a stake of 52,215 shares — an estimated $3.46M sold.

McKinley Capital Management first reported a position in ANIP in Q1 2016 and held it in 3 quarters. The position peaked at $3.46M in Q3 2016. 157 funds tracked by Wall St. Rank hold ANIP as of Q4 2016.

  • McKinley Capital Management reported no remaining ANI Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • McKinley Capital Management sold 52,215 ANI Pharmaceuticals shares in Q4 2016, an estimated $3.46M.
  • McKinley Capital Management first reported a position in ANI Pharmaceuticals in Q1 2016 and held it in 3 quarters.
  • McKinley Capital Management's ANI Pharmaceuticals position peaked at $3.46M in Q3 2016.
  • 157 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q4 2016.

Based on McKinley Capital Management's 13F filing for Q4 2016, filed 14 Feb 2017.